Prescription drug · BLA
Loqtorzi (toripalimab-tpzi) NDC 70114-340
Toripalimab 240 mg/6mL · Injection · Intravenous · Coherus Oncology, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70114-340-01 | 70114034001 | 1 VIAL, GLASS in 1 CARTON (70114-340-01) / 6 mL in 1 VIAL, GLASSMarketed from Oct 27, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Loqtorzi
- Generic name (nonproprietary)
- toripalimab-tpzi
- Active ingredients
- Toripalimab — 240 mg/6mL
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- Coherus Oncology, Inc.
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761240
- Marketing start
- Listing expires
- Other FDA classes
- Programmed Death Receptor-1-directed Antibody Interactions (Mechanism)
- Identifiers
- Product ID 70114-340_8a0ceb7f-ea10-4b90-97fb-530d5f2a0bd2SPL ID 8a0ceb7f-ea10-4b90-97fb-530d5f2a0bd2SPL set ID 82e7921a-1e84-4988-9799-0ad7d19b2a75RxCUI 2669413, 2669420UNII 8JXN261VVA
- Pharmacologic class
- Programmed Death Receptor-1 Blocking Antibody
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N470114034001followed by a unit qualifier and the quantityPackage 70114-0340-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1.2 ) 1.1 First-line Treatment of Metastatic or Recurrent, Locally Advanced NPC with Cisplatin and Gemcitabine LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyng…
Excerpt only. Read the full label for complete information.